Evidence map›Paper›PMID 32527198›Full record

ArticleCirculation research2020

B55α/PP2A Limits Endothelial Cell Apoptosis During Vascular Remodeling: A Complementary Approach To Disrupt Pathological Vessels?

Manuel Ehling, Ward Celus, Rosa Martín-Pérez, Roser Alba-Rovira, Sander Willox, Donatella Ponti, Maria C Cid, Elizabeth A V Jones, Giusy Di Conza, Massimiliano Mazzone

Open access · greenAbstract read
In one paragraph

Article in Circulation research, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 21 papers.

0numbers the graph read from it
0cells of the map it votes in
21citing papers in PubMed
1.9field-weighted citation impact, top 14% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

21 citing papers in PubMed, 36 citations in OpenAlex.

  1. Article
  2. Article
  3. Review
  4. Article
  5. Article
  6. Review
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. Article
  13. Review
  14. Review
  15. Article
  16. Article
  17. Review
  18. Article
  19. Biphasic Effect of Pirfenidone on Angiogenesis.Frontiers in pharmacology · 2021
    Article
  20. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

10 authors at 3 institutions in 3 countries.

Manuel EhlingFrom the Laboratory of Tumor Inflammation and Angiogenesis, Center for Cancer Biology (CCB), VIB, Leuven, Belgium (M.E., W.C., R.M.-P., R.A.-R., S.W., D.P., G.D.C., M.M.).
Ward CelusFrom the Laboratory of Tumor Inflammation and Angiogenesis, Center for Cancer Biology (CCB), VIB, Leuven, Belgium (M.E., W.C., R.M.-P., R.A.-R., S.W., D.P., G.D.C., M.M.).
Rosa Martín-PérezFrom the Laboratory of Tumor Inflammation and Angiogenesis, Center for Cancer Biology (CCB), VIB, Leuven, Belgium (M.E., W.C., R.M.-P., R.A.-R., S.W., D.P., G.D.C., M.M.).
Roser Alba-RoviraFrom the Laboratory of Tumor Inflammation and Angiogenesis, Center for Cancer Biology (CCB), VIB, Leuven, Belgium (M.E., W.C., R.M.-P., R.A.-R., S.W., D.P., G.D.C., M.M.).
Sander WilloxFrom the Laboratory of Tumor Inflammation and Angiogenesis, Center for Cancer Biology (CCB), VIB, Leuven, Belgium (M.E., W.C., R.M.-P., R.A.-R., S.W., D.P., G.D.C., M.M.).
Donatella PontiFrom the Laboratory of Tumor Inflammation and Angiogenesis, Center for Cancer Biology (CCB), VIB, Leuven, Belgium (M.E., W.C., R.M.-P., R.A.-R., S.W., D.P., G.D.C., M.M.).
Maria C CidVasculitis Research Unit, Department of Autoimmune Diseases, Hospital Clínic, University of Barcelona, Institut d'Investigacions Biomèdiques August Pi I Sunyer (IDIBAPS), Barcelona (R.A.-R., M.C.C.).
Elizabeth A V JonesDepartment of Cardiovascular Sciences (E.A.V.J.), KU Leuven, Belgium.
Giusy Di ConzaFrom the Laboratory of Tumor Inflammation and Angiogenesis, Center for Cancer Biology (CCB), VIB, Leuven, Belgium (M.E., W.C., R.M.-P., R.A.-R., S.W., D.P., G.D.C., M.M.).
Massimiliano MazzoneFrom the Laboratory of Tumor Inflammation and Angiogenesis, Center for Cancer Biology (CCB), VIB, Leuven, Belgium (M.E., W.C., R.M.-P., R.A.-R., S.W., D.P., G.D.C., M.M.).
VIB-KU Leuven Center for Cancer Biology · BEConsorci Institut D'Investigacions Biomediques August Pi I Sunyer · ESKU Leuven · BE

Funding

European Research Council 773208
6 · The paper itself

Abstract

rationaleHow endothelial cells (ECs) migrate and form an immature vascular plexus has been extensively studied. Yet, mechanisms underlying vascular remodeling remain poorly established. A better understanding of these processes may lead to the design of novel therapeutic strategies complementary to current angiogenesis inhibitors.

objectiveStarting from our previous observations that PP2A (protein phosphatase 2) regulates the HIF (hypoxia-inducible factor)/PHD-2 (prolyl hydroxylase 2)-constituted oxygen machinery, we hypothesized that this axis could play an important role during blood vessel formation, tissue perfusion, and oxygen restoration. METHODS AND

resultsWe show that the PP2A regulatory subunit B55α is at the crossroad between vessel pruning and vessel maturation. Blood vessels with high B55α counter cell stress conditions and thrive for stabilization and maturation. When B55α is inhibited, ECs cannot cope with cell stress and undergo apoptosis, leading to massive pruning of nascent blood vessels. Mechanistically, we found that the B55α/PP2A complex restrains PHD-2 activity, promoting EC survival in a HIF-dependent manner, and furthermore dephosphorylates p38, altogether protecting ECs against cell stress occurring, for example, during the onset of blood flow. In tumors, EC-specific B55α deficiency induces pruning of immature-like tumor blood vessels resulting in delayed tumor growth and metastasis, without affecting nonpathological vessels. Consistently, systemic administration of a pan-PP2A inhibitor disrupts vascular network formation and tumor progression in vivo without additional effects on B55α-deficient vessels.

conclusionsOur data underline a unique role of the B55α/PP2A phosphatase complex in vessel remodeling and suggest the use of PP2A-inhibitors as potent antiangiogenic drugs targeting specifically nascent blood vessels with a mode-of-action complementary to VEGF-R (vascular endothelial growth factor receptor)-targeted therapies. Graphical Abstract: A graphical abstract is available for this article.

Indexed as

ApoptosisNeovascularization, PathologicVascular RemodelingAngiogenesis InhibitorsAnimalsBreast NeoplasmsCarcinoma, Lewis LungCell Line, TumorEndothelial CellsEnzyme InhibitorsFemaleHumansHuman Umbilical Vein Endothelial CellsHypoxia-Inducible Factor-Proline DioxygenasesMaleMice, Inbred C57BLAngiogenesis InhibitorsEGLN1 protein, humanEgln1 protein, mouseEnzyme InhibitorsHypoxia-Inducible Factor-Proline Dioxygenasesp38 Mitogen-Activated Protein KinasesPPP2R2A protein, humanPpp2r2a protein, mouseProtein Phosphatase 2apoptosisblood vesselsdevelopmental biologyendothelial cellsoncologyperfusionvascular endothelial growth factor

Identifiers

PMID32527198
PMCPMC7616433
OpenAlexW3034961350

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.